Skip to main content
Fig. 2 | BMC Urology

Fig. 2

From: Free combination of dutasteride plus tamsulosin for the treatment of benign prostatic hyperplasia in South Korea: analysis of drug utilization and adverse events using the National Health Insurance Review and Assessment Service database

Fig. 2

Risk of any AE or SAE among patients with prevalent BPH receiving free combination therapy compared with dutasteride 0.5 mg monotherapy (A: AE, C: SAE) or tamsulosin 0.4 mg monotherapy (B: AE, D: SAE). For the purpose of this analysis, the data on prostate cancer were included in the risk calculations for any AE and any SAE. AE, adverse event; BPH, benign prostatic hyperplasia; CI, confidence interval; NIM, non-inferiority margin; RR, risk ratio; SAE, serious adverse event

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us